IP Library Granted Patent US 9,605,048
Granted Patent B2
US 9,605,048 · App. 13/146,758 · Granted Mar 28, 2017

Human soluble CD146, preparation and uses thereof

Inventors: Marcel Blot-Chabaud (Fuveau, FR); Karim Harhouri (Marseilles, FR); Nathalie Bardin (Marseilles, FR); Benjamin Guillet (Aix en Provence, FR); Françoise Dignat-George (Marseilles, FR)
Assignees: UNIVERSITE D'AIX-MARSEILLE; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
C07K14/70503A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,605,048
App. No.
13/146,758
Granted
Mar 28, 2017
Kind
B2
Abstract

The present invention relates to compositions and methods for modulating angiogenesis in vivo, ex vivo or in vitro. More particularly, the invention relates to a soluble CD 146 protein usable in the context of human therapy, as well as to corresponding antibodies. Particular forms of CD 146, herein described, may be used to mobilize, in vivo or ex vivo, both mature and immature endothelial cells, as well as to increase their influence on angiogenesis. The invention also relates to compositions comprising such compounds, particularly pharmaceutical or diagnostic compositions, including kits and the like, as well as methods of therapy or diagnosis using said compounds, compositions and cells.

Claims (9)

1. A composition comprising human soluble CD146 protein consisting of SEQ ID NO: 7, wherein said human soluble CD146 protein is acetylated, methylated, phosphorylated or fused to another polypeptide and a pharmaceutically acceptable carrier.

2. The composition according to claim 1 , further comprising an angiogenic factor selected from the group consisting of vascular endothelial growth factor (VEGF), stromal-cell-derived-factor-1 (SDF- 1 ), basic fibroblast growth factors (bFGF), erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), stem cell factor (SCF), interleukin-8 (IL-8) and mixtures thereof.

3. The composition according to claim 1 , further comprising an endothelial progenitor cell (EPC), said cell having, optionally, been contacted with said human soluble CD146 protein.

4. A method of treating limb ischemia in a mammal comprising administering to the mammal an isolated human soluble CD146 protein consisting of SEQ ID NO: 7, said human soluble CD146 protein being optionally acetylated, methylated, phosphorylated, glycosylated or fused to another polypeptide, or a composition comprising said soluble CD146 protein and a pharmaceutically acceptable carrier.

5. An isolated human soluble CD146 protein consisting of SEQ ID NO: 7, wherein said human soluble CD146 protein is acetylated, methylated, phosphorylated or fused to another polypeptide.

6. The isolated human soluble CD146 protein of claim 5 , wherein said human soluble CD146 protein is acetylated.

7. The isolated human soluble CD146 protein of claim 5 , wherein said human soluble CD146 protein is fused to another polypeptide.

8. The isolated human soluble CD146 protein of claim 5 , wherein said human soluble CD146 protein is methylated.

9. The isolated human soluble CD146 protein of claim 5 , wherein said human soluble CD146 protein is phosphorylated.

Assignments (2)
MERGER Recorded Jan 20, 2017
From: UNIVERSITE DE LA MEDITERRANEE
To: UNIVERSITE D'AIX-MARSEILLE
Reel/Frame 041022/0064 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2011
From: BLOT-CHABAUD, MARCEL; HARHOURI, KARIM; BARDIN, NATHALIE; GUILLET, BENJAMIN; DIGNAT-GEORGE, FRANCOISE
To: UNIVERSITE DE LA MEDITERRANEE; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Reel/Frame 026898/0901 →
Priority Claims (1)
EP 09305093 · Jan 30, 2009 · regional
Continuity (1)
Related Publication 20110286963A1 · Nov 24, 2011